Table 1.
Summary statistics of the study sample
| Baseline Characteristics | Summary Statistics | ||
|---|---|---|---|
| Stable/Decline (n=45) | Decline/Stable (n=29) | All 74 Patients | |
| Age at randomization (yr) | 53.1 (45.6, 57.8) | 54.9 (44.5, 62.1) | 53.7 (45.5, 58.9) |
| Women | 13 (28.9) | 12 (41.4) | 25 (33) |
| Baseline eGFR (ml/min per 1.73 m2)a | 49.7 (41.1, 57.3) | 60.6 (55.4, 68.0) | 55.8 (44.1, 61.8) |
| Baseline urine protein-to-creatinine ratio (g/g) | 0.05 (0.02, 0.12) | 0.05 (0.03, 0.11) | 0.05 (0.02, 0.11) |
| Duration of stable periods (mo) | 51 (41, 57) | 49 (41, 58) | 50 (41, 58) |
| Duration of decline periods (mo) | 34 (24, 50) | 28 (24, 41) | 32 (24, 42) |
| AASK randomized intervention: mean arterial pressure goal | |||
| ≤92 mmHg | 18 (40) | 14 (48.3) | 32 (43) |
| 102–107 mmHg | 27 (60) | 15 (51.7) | 42 (57) |
| AASK randomized intervention: antihypertensive drugsb | |||
| Ramipril | 19 (42.2) | 10 (34.5) | 29 (39) |
| Metoprolol | 18 (40) | 11 (37.9) | 29 (39) |
| Amlodipine | 8 (17.8) | 8 (27.6) | 16 (22) |
| Average eGFR on segments of estimated trajectory (ml/min per 1.73 m2) | |||
| On stable periods | 53.6 (46.3, 61.6) | 39.1 (28.4, 46.2) | 48.5 (37.2, 58.0) |
| On decline periods | 34.7 (29.5, 52.8) | 52.6 (44.0, 59.8) | 43.1 (31.8, 54.8) |
Continuous variables were summarized by median (25th and 75th percentiles). Categorical variables were summarized by number (percentage).
a
Averaged over two baseline values, <3 months apart.
b
The randomized antihypertensive drugs were allocated in 2:2:1 ratio. Amlodipine was stopped 3 years after randomization.